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CHAPTER I
INTRODUCTION
Attention Deficit Disorder
Attention deficit disorder (ADD), formerly known as
hyperkinetic syndrome or minimal brain dysfunction, is
characterized predominantly by d e v e 1 o p m e n t a 1 1
y
inappropriate inattention and impulsivity, as well as
hyperactivity which is of a poorly organized and non
goal-directed nature. Associated features vary as a
function of age and may include mood lability, a low
frustration tolerance, poor self-esteem, stubbornness,
negativism, bossiness, bullying, obstinacy, temper
outbursts and a lack of response to discipline. "Soft"
neurological signs such as clumsiness as well as
p e r c e p t ua 1 - m o t or dysfunctions, e.g., poor eye-hand
coordination, may also be present (American Psychiatric
Association [APA], 1980). Prevalence rates for ADD vary
from 3% ( APA, 1980) to as high as 5-10$ of prepubertal
children (Wender, 1975). Although typically thought of
as a disorder of childhood and, not uncommonly,
adolescence, recent reports in the literature suggest its
persistence into adulthood where its existence may
be
1
concealed by a variety of different diagnostic labels
(Wood, Reimherr, Wender and Johnson, 1976; Mann and
Greenspan, 1976; Huey, Zetin, Janowsky, and Judd, 1978;
Bellak, 1979; Bellak and Charles, 1979; Huessy, Blair and
Rood, 1979; Wender, Reimherr, and Wood, 1981; Yellin,
Hopwood and Greenberg, 1982).
Huey et al. (1978) and Bellak and Charles (1979)
have treated adult patients previously diagnosed as
schizophrenic with symptoms characteristic of ADD who
were poor responders to antipsychotic medications yet did
well on medication known to be effective in the treatment
of ADD, e.g., the catecholamine agonist m e t hy 1 phe ni da t
e
and the tricyclic antidepressant imipramine. The APA
(1980), reflecting this relatively new awareness of the
persistence of symptoms into adult life, has created a
diagnostic category for the disorder in adults called
ADD, Residual Type.
In children, the most effective treatment regimen
typically includes stimulant medication (methylphenidate,
pemoline, or d- am ph e t am i ne ) in combination with an
operant conditioning approach to the management of
behavior (Wender, 1971). In adults, central nervous
system stimulants have also proved effective but
often
the preferred medication seem to be tricyclic
3antidepressants, most typically imipramine (Huessy et
al,, 1 979). In some cases, imipramine is the drug of
choice because it is less subject to abuse than d-
amphetamine or m ethyl pheni date.
Amphetamine and amphetamine like compounds
(methylphenidate) act as central nervous system
stimulants in that they potentiate the release of the
neurotransmitters dopamine (DA) and norepinephrine (NE)
from presynaptic nerve terminals and inhibit their
intracellular reuptake (Kuczenski, 1983). Whereas
amphetamine seems to release, preferentially, newly
synthesized pools of DA, methylphenidate facilitates the
release of stored or vesicular pools (Chieuh and Moore,
1975). In so doing these compounds facilitate
neurotransmission in select groups of neurons by making
more of the transmitter available at the synapse.
The try cyclic antidepressants are believed to exert
their pharmacologic effect via reuptake inhibition of NE
and serotonin (5-HT) , another central nervous system
neurotransmitter (Iversen and Mackay, 1979). Imipramine,
in particular, has been found to be a more potent NE than
5-HT reuptake inhibitor (Green and Nutt, 1983),
although
in rat brain high affinity 3 H- i m i pr am i ne binding sites
have been found to be selectively located
presy naptically
on 5-HT neurons (Gross, Gothert, Ender, and Schumann,
1981).
On the basis of the favorable response of children
and adolescents to the psychostimulants and
antidepressant drugs, and in view of what is known about
the mechanism of drug action both behaviorally and
neurochemically , Wender (1971 » 1 975, 1 978) hypothesized
that ADD involves a functional underactivity of one or
more of the central nervous system monoamines (NE, DA,
and/or 5-HT) due to decreased synthesis, release or
receptor sensitivity. There have been some attempts to
document this hypothesized neurochemical abnormality in
humans. Shawitz, Cohen and Bowers (1977) found
significantly lower levels of homovanillic acid ( HV A) in
the cerebral spinal fluid (CSF) of a clinically
homogeneous group (N=6) of ADD children as compared with
controls (N=26). Both groups had been pretreated with
probenecid (100-150 mg/kg, orally), a drug which blocks
the removal of acidic monoamine metabolites from CSF.
CSF concentrations of 5-hy droxyindolecetic acid
(5-HIAA),
the principle metabolite of 5-HT, were not significantly
different between groups. The results suggest that
there
may be an abnormality in DA turnover in the brains of ADD
chil dren.
5This presumed biochemical dysfunction affects
behavior primarily by the impairment it produces in the
putative reward and punishment centers of the brain.
This impairment is expressed as a diminished capacity for
positive and negative affect, the subjective nature of
which is a reduction in the capacity to experience both
psychic pain, e.g., guilt, remorse, and psychic pleasure
(anhedonia). Outwardly, it is manifested as a decreased
responsitity to reward and punishment, i.e., to operant
conditioning. This hypothesis is consistent with a large
body of animal data on the reward and punishment centers
of the brain including the potentiation of previously
rewarded behavior, and the further suppression of
previously punished behavior by the administration of
substances which increase the levels of one or more of
these central nervous system monoamines (Stein, 1964;
Stein and Wise, 1970; Wise, Berger and Stein, 1973;
Stein, Wise and Belluzzi, 1 977).
Since the initial discovery by Olds and Milner
(1954) that electrical stimulation of certain discrete
areas of the brain could serve as a reward, and by
Delgado, Roberts and Miller (1954) that stimulation of
different discrete areas had punishing effects,
researchers have attempted to investigate the
neurochemical basis of these phenomena, and evidence has
accumulated that monoaminergic systems are involved.
Work by Dewit and Wise ( 1 977 ), Routtenberg ( 1 978) and
Wise (1980) have suggested that DA plays the critical
role in brain reward. Anatomically, brain reward has
been found at specific locations extending from the
frontal cortex to the midbrain and into the hindbrain,
and passing through the medial forebrain bundle in the
hypothalamus. Although both NE and DA systems overlap in
much of the area giving rise to intracranial self-
stimulation behavior in rats, only DA fibers are confined
to areas that mediate brain reward, whereas NE fibers
extend into other regions (Routtenberg, 1978). Wise
(1980) found self- stimulation to be uniquely associated
with the layer of D A-cont aining cells in the substantia
nigra and ventral tegmentum. The occurrence of robust,
low threshold stimulation from DA cells and the lack of
occurrence of self- stimulation from bordering areas
suggest a unique involvement of DA cells or their
afferents in brain stimulation reward in at least these
anatomical sites.
The neurochemical basis for punishment, on the other
hand, appears to involve serotonergic systems
(Stein and
Wise, 1974; Stein, Wise and Belluzzi, 1977). Wise
et al.
7(1973) observed suppression of self-stimulation and
increased suppression of punished behavior in rats with
intraventricular injections of 5-HT and the alpha-
nor adr energi c antagonist phentolamine, whereas injections
of p - c hi or o ph e ny 1 al a ni ne (PCPA), a 5-HT synthesis
inhibitor, produced increased rates of punished behavior.
This latter effect was reversed after intraperitoneal
injections of the serotonin precursor, 5-HTP.
Although known to be effective in relieving the
symptoms associated with ADD, drugs which potentiate
m o noam i ner gi c systems often have undesirable side
effects. The most common side effects seen in children
who are taking me thyl phe ni date are anorexia and insomnia
(Bassuk and Schoonover, 1977) Tachycardia, abdominal
pain, and a lowering of the seizure threshold in children
with a history of seizures or EEG abnormalities have also
been observed. Common imipramine side effects include
dry mouth, decreased intestinal motility, urinary
retention, blurred vision and sedation (Bassuk and
Schoonover, 1977). These side effects, understandably,
are areas of concern to parents and professionals
involved in the treatment of ADD children.
8Precursor Control of Neurotrana m ij^n
Synthesis and Release
Recently, researchers in the area of nutrition and
behavior have demonstrated an increase in the synthesis
and release of the monoamine neurotransmitters with the
administration of the appropriate amino acid precursor,
e.g., tyrosine in the case of DA and NE; tryptophan in
the case of 5-HT (Fernstrom and Wurtman, 1971, 1974;
Wurtman, Larin, Mostafapour and Fernstrom, 1974; McBride,
Hyde, Smith, Lane and Aprison, 1976; Wurtman, 1976;
Gibson and Wurtman, 1977, 1978; Sved, Fernstrom and
Wurtman, 1 979; Melamed, Hefti and Wurtman, 1 980; Wurtman,
1982; Conlay and Zeisel, 1982).
Since tyrosine and tryptophan are readily available
from protein products normally present in the diet, and
as nutritional supplements in many health food stores, a
question now emerges, "Can these amino acid precursors be
used in place of or as a supplement to pharmacotherapy in
the treatment of ADD?" If so, then the potentially
harmful side effects of the central nervous system
stimulants and the tricyclic antidepressants may be
reduced or avoided altogether. In addition,
parents,
teachers, and physicians now opposed to medicating
young
9children may be more open to a nutritional approach to
therapy thus making effective treatment available for a
larger number of ADD children.
Since the late 60's and early 70's, the relationship
between nutrition and brain function has been the focus
of intense investigation by Richard Wurtman and his
colleagues. One of their earliest findings (Shoemaker
and Wurtman, 1973) was that the brains of 24 day old
weanling rats given a diet deficient in protein (8%
protein) contained abnormally low levels of DA and NE as
compared with controls (24% protein). This observation
suggested that precursor availability may play a
significant role in the control of CA synthesis.
In a subsequent study (Wurtman et al., 1974), the
effect of tyrosine injections (i.p.) on brain CA
synthesis was estimated by measuring 3,4-
dihydroxyphenylalanine (DOPA) accumulation after
administration of the aromatic amino acid decarboxylase
inhibitor R04-4602. Administration of 50 mg/kg of
tyrosine produced an 81% increase in brain tyrosine and a
13* increase in DOPA (P<.05). In contrast, the
brains of
rats given either tryptophan (50 mg/kg) or leucine (100
mg/kg), amino acids known to compete with
tyrosine for
uptake into brain, contained significantly less tyrosine
1 0
and DO PA than controls. These findings supported the
hypothesis that nutritional factors may play an important
role in CA synthesis by controlling the availability of
tyrosine
.
Confirming these findings, Gibson and Wurtman (1977)
looked at the relationship between DA and NE synthesis
and brain tyrosine concentration. CA synthesis was again
estimated by DOPA accumulation and measurements were
taken 30 or 60 minutes after the administration of R04-
4602. In general, treatments that raised or lowered
brain tyrosine concentrations were found to cause
significant parallel changes in DOPA accumulation rates.
The possibility exists that exogenous tyrosine may
*
differentially effect DA and NE synthesis. Oishi and
Szabo (1984) found that tyrosine injection (51.2 mg/100
g) significantly increased DA levels in rat striatum and
cortex without markedly altering NE levels. Using DOPA
accumulation as the only measure of CA synthesis may, as
they have suggested, tend to disregard these differences.
Brain tyrosine concentrations have been shown to
influence not only the synthesis but also the release of
CAs. In a study by Gibson and Wurtman (1978), injections
of tyrosine (100 mg/kg, i.p.) produced a significant
increase in the accumulation of the major NE metabolite,
11
3- me thoxy-4- hydroxy- phenyl ethylene glycol- sulfa te ( MO PEG-
so 4), after treatment with probenecid, a drug which
blocks the efflux of M0PEG-S04 from brain -
In this same study, Gibson and Wurtman looked at the
effect of cold stress (4°C for 1 h) on M0PEG-S04
accumulation after pretreatment with tyrosine (125 mg/kg)
or after the consumption of a single protein rich meal
(40$ casein). (Placing rats in a cold environment is
known to increase NE turnover [Meek and Neff, 1973])-
Significant increases in brain MOPEG-SO^ levels were seen
under both conditions.
Morre, Hefti and Wurtman (1980) investigated
regional variations in tyrosine concentrations in the
brains of rats given 1-tyrosine (100 mg/kg, i.p.) and the
time course of these changes. Tyrosine administration
significantly increased tyrosine concentrations in all
areas of the brain. However, relative increases in the
various regions differed; high relative increases were
observed in areas of low initial concentrations and vice
versa, resulting in a more uniform di str i butr i on of
tyrosine in brain tissue. Increases were maximal 1 hour
after tyrosine administration and gradually declined over
the next 3 hours. The highest relative increases
were
observed in cortex and hippocampus. Co-administration of
12
1-valine (500 mg/kg), a large neutral amino acid known to
compete with tyrosine for transport into brain,
completely blocked this effect.
Increased tryptophan availability has also been
shown to increase neurotransmitter synthesis;
specifically 5-HT synthesis. Fernstrom and Wurtman
(1971) found significant elevations in both brain
tryptophan and 5-HT one hour after rats received
injections of 1-tryptophan (12.5, 25, 50, or 125 mg/kg,
i.p.). McBride, Hyde, Smith, Lane and Aprison (1976)
analyzed nerve ending fractions from the telencephalon of
pigeons given intramuscular injections of 1-tryptophan
(300 mg/kg) and found significantly increased levels of
tryptophan, 5-HT, and 5-HIAA, suggesting that both
synthesis and release can be influenced by tryptophan
pr etreatment
.
An unexpected finding (Fernstrom and Wurtman, 1974)
was that rats fed a diet rich in carbohydrate and low in
protein had increased brain levels of tryptophan and 5-
HT, whereas a diet rich in protein and low in
carbohydrate produced decreased levels. This was
contrary to expectation, as tryptophan is an essential
amino acid and, as such, cannot be synthesized in vivo.
Whatever tryptophan one has can only be obtained
through
13
the ingestion of dietary protein. This is not true for
all amino acids; tyrosine, for example, can be
synthesized in the liver from phenylalanine, another
essential amino acid.
This apparent paradox was finally resolved by the
consideration of the following: First, tryptophan is a
large, neutral amino acid which cannot cross the blood-
brain barrier and so is transported across it by a
carrier molecule. Second, as a neutral amino acid, it
competes with five other large neutral amino acids
(leucine, isoleucine, valine, phenylalanine and tyrosine)
for the same transport molecule for uptake into brain.
Third, as much as 80$ of all plasma tryptophan molecules
are bound to albumin, a protein normally present in
blood. Fourth, it is the total amount of tryptophan in
plasma, i.e., al bum i n- bo un d plus free tryptophan, that
determines the amount that is potentially accessible to
the brain. Fifth, a diet rich in carbohydrate stimulates
the secretion of insulin which in turn lowers the plasma
concentrations of competing amino acids more than it does
that of tryptophan. Because approximately 80% of the
available tryptophan is bound to albumin, it is
essentially free from the effect of insulin; more
tryptophan is therefore available, pr o p or t u na
t e 1 y
,
for
14
transport into brain. Fifth, a protein-rich meal, on the
other hand, will reduce brain levels of 5-HT by elevating
the relative levels of the other neutral amino acids in
the bloodstream which compete for transport into brain.
The net effect is that less tryptophan is carried across
the blood-brain barrier and less reaches the neurons
where 5-HT synthesis takes place.
An additional part of this paradox involves the role
of non-e sterif i ed fatty acids (NEFA) which appear to
modulate the binding of tryptophan to albumin in plasma
(Madras, Cohen, Messing, Munro, and Wurtman, 1974). The
affinity of NEFA for albumin is apparently greater than
that of tryptophan for albumin. When insulin is
secreted, plasma levels of NEFA fall because insulin
facilitates the uptake of NEFA into fat-producing cells.
As these NEFA are stripped off the circulating albumin,
the affinity of albumin for tryptophan increases; hence,
plasma levels of al bum i n- bound tryptophan rise. When
albumin-bound tryptophan molecules pass through brain
capillaries, they readily dissociate from albumin because
the affinity of the blood-brain transport system for
tryptophan is considerably greater than the affinity of
albumin for tryptophan (Wurtman and Pardridge, 1979;
Wurtman, Hefti, and Melamed, 1981).
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Although the intake of both tyrosine and tryptophan
may influence the synthesis and turnover of their
respective neurotransmitters, the mechanism by which they
do so appears to differ. Understanding this difference
involves, among other factors, knowledge of the steps
involved in the biosynthesis of the CAs and 5-HT. In
both cases, the initial step involves hy droxylation of
the precursor by enzymatic reaction. These reactions are
catalyzed by two specific enzymes, tyrosine hydroxylase
and tryptophan hydroxylase, respectively. The activities
of these enzymes have been demonstrated to be rate-
limiting in nature in the sense that reductions in the
activities of these enzymes parallel decreases in
neurotransmitter synthesis (Lovenberg, Jequier and
Sjoerdsima, 196 8).
It has been demonstrated that both enzymes use a
reduced pteridine as a cofactor (Nagatsu, Levitt and
Udenfriend, 1964; Lovenberg, Jequier and Sjoerdsma,
1968). Apparently CAs can compete with this cofactor for
attachment to the binding site on tyrosine hydroxylase
thereby inhibiting the hy droxylation of tyrosine and
therefore CA synthesis (Udenfriend, Zal tman-Nir enber g,
and Nagatsu, 1965; Weiner, 1970). In contrast, serotonin
does not appear to exert a significant direct
inhibitory
16
effect on tryptophan hydroxylase so it does not suppress
its own biosynthesis (Jacoby, Colmenares, and Wurtman,
1975). As tryptophan hydroxylase is a low affinity
enzyme and therefore not saturated with its substrate in
vivo, increased levels of tryptophan can lead to
increased levels of brain 5-HT. This suggests that one
important regulator of 5-HT synthesis may simply be the
intake of dietary tryptophan (Fernstrom and Wurtman,
1971 )
.
Although tyrosine hydroxylase is also of the low
affinity type, i.e., not saturated with its substrate in
vivo, increased levels of its precursor do not
necessarily produce increased levels of neurotransmitter
due to the influence of endproduct inhibition. Rather it
appears that certain conditions must be present for
increased tyrosine intake to induce increases in CA
synthesis and release. Wurtman (1982) and Melamed et al.
(1980) have raised the possibility that, in CA neurons,
tyrosine's effect on neurotransmitter synthesis and
release may vary with neuronal activity, becoming
important when neurons are firing frequently but not when
they are relatively quiescent. In an earlier study,
Scally, Ulus and Wurtman (1977) found that levels
of HVA
were significantly elevated in the striata of rats given
17
tyrosine (100 mg/kg) and the DA receptor blocker,
haloperidol (2 mg/kg) but not in animals given tyrosine
plus probenecid (200 mg/kg). Haloperidol increases DA
turnover due to receptor blockade. Probenecid, on the
other hand, blocks the egress of organic acids from CSF
and has no effect on DA turnover. The failure of HVA
levels to vary with brain tyrosine in probenecid animals
was attributed to end-product inhibition; the increase in
HVA accumulation in haloperidol animals, to an inhibition
of this feedback mechanism. To examine the possibility
that the failure of tyrosine administration to accelerate
HVA accumulation in probenecid animals resulted from a
feedback mediated change in the kinetic properties of
ty r osi ne hy dr oxy lase , th ey m easur ed the enzyme's af f ini ty
for tyrosine and for its pteridine cofactor, DMPHjj (2-
amino-4-hy dr oxy -6
,
7 -dim e thy 1- 5 , 6 ,7 , 8- te tr ahy dr opt er i di ne
hydrochloride), on brain samples from each experimental
group. Haloperidol administration with or without
tyrosine significantly reduced the K m of tyrosine
hydroxylase for DM PH ^ as compared to probenecid
administration.
Badawy and Williams ( 1 982 ) have suggested that the
ability of exogenous tyrosine to enhance CA synthesis
may
be dose related. In rats, tyrosine doses of up to 40
18
mg/kg were found to produce significant increases in DOPA
accumulation in brain but only the 20 mg/kg dose
increased brain DA, DOPAC, and NE to a significant
degree. Doses of 50 mg/kg and over abolished this
enhancement. The fact that small doses enhanced CA
synthesis is consistent with the idea that tyrosine
hydroxylase is normally unsaturated with its substrate in
vivo and can become more fully saturated by increasing
the availability of tyrosine. Badawy and Williams
suggest that the failure of larger doses to enhance CA
synthesis may be due to substrate inhibition of tyrosine
hydroxylase activity.
Melamed et al. (1980) examined the relationship
between the apparent firing rates of ni gr o s t r i a t al
neurons, DA release and tyrosine availability. Partial,
unilateral nigrostriatal lesions of varying severity were
produced in rats by injecting graded doses of 6-
hy droxydopamine into the substantia nigra. In surviving
ipsilateral nigrostriatal neurons, the formation of the
DA metabolites, DOPAC and HVA, increased significantly in
rats with severe lesions (DA concentrations less than 25%
of control values in contralateral unlesioned striata)
but remained unchanged in rats with less severe lesions,
in animals with significantly enhanced DA metabolite
19
formation, i.e., those with severe lesions,
administration of tyrosine (250 mg/kg) but not valine
(500 mg/kg) lead to further significant increases in HVA
and DOPAC. These findings suggest that after severe
damage to nigrostriatal neurons, remaining populations of
striatal neurons increase their firing rate and
accelerate DA synthesis and release. Under these
conditions, increased tyrosine availability appears to
enhance DA synthesis and release.
Having established that exogenous supplies of at
least two nutrients, tyrosine and tryptophan, could
influence the synthesis of their neurotransmitter
products, it became possible for Wurtman (1982) to
formulate some general principles for predicting whether
a given neurotransmitter might be under this type of
precursor control. First, the exogenously supplied
precursor must significantly elevate the plasma level of
the precursor and the level cannot be held constant by
feedback mechanisms like those regulating plasma pH for
exam pie. Second, the precursor must be able to penetrate
the blood-brain barrier and the concentration of the
precursor in brain must depend on and fluctuate with the
concentration in plasma. Third, carrier molecules
that
transport the precursor across the blood-brain barrier
20
must be of the low-affiniy type, i.e., the transport
mechanism must be unsaturated with its substrate so that
it can become more fully saturated when plasma levels
rise. Fourth, the enzyme that catalyzes the conversion
of the precursor to neurotransmitter must also be of the
low -affinity ty pe. Finally, the catalyzing enzyme must
be relatively free of end-product inhibition when the
intracellular level of its product, the neurotransmitter,
rises.
All these biochemical conditions have been
demonstrated to be fulfilled in the case of 5-HT. All
but the last condition has been shown to be fulfilled in
the case of the CAs where, as previously stated,
tyrosine's effect on synthesis and release appears to
vary with neuronal activity, becoming important when
neurons are firing frequently but not when they are
relatively quiescent.
Amino Acid Precursors in the Treatment
of ps ychiatric Disorders
It is interesting
neurotransmitters include the
known to be affected by drugs
that the responsive
CAs and 5-HT, transmitters
used to treat psychiatric
21
disorders such as depression and ADD. There already have
been several reports in the literature of the use of
amino acid precursor to treat depression (Coppen,
Whybrow, Noguera, Maggs, and Prange, 1972; Jensen et al.,
1975; Walinder, Skott, Carlsson and Roos, 1976;
Gelenberg, Wojcik, Growdon, Sved and Wurtman, 1 980 ;
Walinder, Carlsson, Persson and Wallin, 1 980; Young,
Chouinard, and Annable, 1981; van Praag, 1983; van Praag
and Mendlewicz, 1983). Gelenberg et al. (1980) employed
a do ubl e- bl i nd, pi ace bo- co ntr ol 1 ed cross over trial of
tyrosine in a 30 year old woman who had suffered from
chronic and recurrent depression for several years and
was diagnosed as having primary depression, unipolar
type. L-tyrosine (100 mg/kg) was administered orally
each day in three doses for two weeks, then placebo at
the same schedule for eighteen days, and finally tyrosine
for an additional five weeks. Symptoms of depression
reportedly decreased dramatically during tyrosine
administration and recurred when placebo was substituted
as measured by the Hamilton Depression Rating Scale and
the Zung Self-Rating Depression Scale. Comparisons
between mean ratings during pr e tr ea tm ent , tyrosine
administration and placebo were statistically
significant
.
22
In a study by Gibson and Gelenberg (19 8 3), a four
week trial of tyrosine (100 mg/kg/day) was effective in
alleviating the symptoms of depression without any of the
adverse side effects which often accompany the use of
tricyclic antidepressants in four out of six unipolar
depressed patients as measured by the Hamilton Rating
Scale.
In a double-blind study by Coppen et al. ( 1 97 2) the
efficacy of 1-tryptophan (9 g/day, n=22) vs. imipramine
(150 mg/day, n=20) in the treatment of primary depression
was compared. Patients reportedly responded as well to
1-tryptophan as they did to imipramine as measured by
their scores on the Hamiltion Rating Scale. In agreement
with this finding is a double-blind study by Jensen et
al. (1975) in which both tryptophan patients (n=22) and
imipramine patients (n=20) showed statistically
significant reductions in symptoms at the end of three
weeks of treatment; however, improvements were more rapid
in the imipramine group.
Walinder et al. (1976) investigated whether the
antidepressant action of clomipramine could be enhanced
by tryptophan. In a double-blind study it was shown that
patients given clomipramine plus dl- try pto phan (0.1 g/kg)
improved more rapidly than the group given clomipramine
23
alone. Clomipramine alone produced an approximately 50%
decrease in CSF 5-HIAA levels, presumably due to a
feedback inhibition of 5-HT turnover induced by reuptake
inhibition. Dl- try pt ophan produced an up to threefold
increase in tryptophan levels in plasma and CSF
sufficient to prevent the clomipr am ine -induced deer ease
in CSF 5-HIAA. An unexpected finding was that in the
clomipramine plus tryptophan group, the level of HV A in
CSF was significantly increased after 12 days of
treatment. The possibility was raised that the change in
5-HT neurotransmission induced by this combination may
have produced a secondary change in DA neurotransmission
via neuronal connections.
Chouinard et al. (1983) present a review of several
studies which used tryptophan in combination with
antidepressant drugs in the treatment of depression. Of
the six studies which supplemented a reuptake i nhibitor
with tryptophan, only one found a significant
potentiation of the antidepressant effect. This study
was the previously cited study by Walinder et al. ( 1 976 ).
Whether tyrosine or tryptophan therapy will
ultimately prove to be safe and effective in a
significant number of patients suffering from depression
remains to be seen. If it is, it might be an attractive
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alternative to the tricyclic antidepressants and the
monoamine oxidase inhibitors which often produce unwanted
side effects.
Similarly, tyrosine and/or tryptophan therapy may be
a more attractive and platable alternative to
m e thy 1 ph e ni da t e or imipramine therapy in children and
adolescents with ADD. To date, as far as can be
determined, there have been no reports in the literature
on the use of either nutrient in the treatment of ADD.
Some indirect evidence that short-term alterations
in diet composition may influence hyperactive behavior in
humans was reported by Chiel and Wurtman (1981) using an
animal model of hyperactive motor behavior. We have
already seen from previously reported studies how the
proportions of protein and carbohydrate in the diet can
affect the amounts of tryptophan and tyrosine transported
into the brain and consequently, the synthesis of 5-HT
and the CAs. Wurtman's study attempted to investigate
changes in the spontaneous nocturnal activity patterns
of
rats fed diets in which the ratio of carbohydrate to
protein was systematically varied. One group of 20
rats
received a diet containing 18$ protein (casein), 57$
carbohydrate (dextrose, sucrose, and dextrin), and 15$
vegetable fat; a second group of 20 rats received no
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protein, 75? carbohydrate, and 15$ fat. The results
indicated that as this ratio increased, rats were more
continuously active as measured by the total number of
infrared photocell beam interruptions in successive 20-
minute periods during dark hours when rats are normally
active. Results were statistically significant (P<.01).
Animals eating the 18$ protein diet showed a highly
irregular pattern of activity during darkness; periods of
intense activity were followed by periods of complete
quiescence. In contrast, rats fed the no protein diet
were almost continuously active during darkness, with few
or no periods of quiescence. No correlation was found
between the number of calories an animal ate, the fat
content of the diet or weight and its activity pattern.
Another indirect indicator that tyrosine therapy may
be beneficial in the treatment of ADD comes from a study
by Heffner and Seiden (1980). This study measured the
synthesis of DA and NE from tyrosine in brain during the
performance of operant behavior. It is well known that
ADD children are difficult to discipline, i.e., to
condition. The threat of punishment or the expectation
of reward seems to have little or no effect on their
behavior. Often a dramatic improvement is seen in their
responsiveness to reward and punishment upon the
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administration of pharmacotherapy (Wender, 1971). As
previously indicated, the medications of use in the
treatment of ADD children increase the levels of DA and
NE in brain. These same neurotransmitters are thought to
underly synaptic activity in the putative reward centers
of the brain, and thus they serve as part of the
neurochemical basis for the process of operant
conditioning. Direct evidence for the involvement of NE
and DA in the operant behavior of rats was found by
Heffner and Seiden.
In their study, synthesis rates of DA and NE were
estimated after the intraventricular injection of
radioactive [3H] tyrosine. A conversion index was used
which expressed the levels of [3H] DA or [3H] NE
accumulated in various brain regions as a function of the
specific activity of [3H] tyrosine. In rats lever
pressing on a fixed ratio 5 schedule of reinforcement,
the DA conversion index in the caudate putamen was 66%
higher than in controls but was not different from
control values in the mesolimbic area and hypothalamus.
The NE conversion index in operant-perf or ming rats was
48$ higher in the hypothalamus than in controls but was
unchanged in the mesolimbic area, telencephalon and brain
stem. Changes in the NE and DA conversion indices seen
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during operant performance were associated with increases
in the brain levels of [3H] DA or [3 H ] NE. The relative
increment in the DA conversion index seen in the caudate
putamen was directly proportional to the number of lever
presses emitted following [3h] tyrosine administration.
Thus it appears that operant behavior is associated with
increases in the rate of the synthesis of DA and NE
within select populations of neurons.
On the basis of data presented thus far, it appears
that tyrosine and/or tryptophan therapy is worthy of
serious consideration in the treatment of ADD.
Specific Aims
The pur pose of the current study, was to assess
whether drugs used in the treatment of ADD, specifically
me thylphenidate and imipr amine, could be potentiated by
exogenous supplies of nutrients which serve as precursors
to the neurotransmitters on which these drugs ultimately
act. Moreover, this study examined the feasibility of an
animal model to investigate these phenomena under more
objective conditions than those afforded by using
clinical patients.
CHAPTER II
METHOD
Subjects
Thirty male Holtzman Albino rats (Holtzman Company,
Madison, HI) approximately 160 days old at the start of
the study and weighing between 300-400 g served as
subjects for this experiment. All animals were housed
singly at a constant temperature (21° C) with a daily
cycle of 12 h light and 12 h dark. Each day immediately
following training and testing procedures, animals were
fed approximately 20 g of Ralston Purina Rodent Lab Chow
5001. Tap water was available ad libit um.
Apparatus
Three standard operant chambers enclosed in sound-
attenuated and fan-ventilated cubicles were used in this
study. Each chamber was equipped with two levers, one on
either side of and equidistant from a centrally located
dipper which delivered 0.1 cc of liquid reinforcement
consisting of a mixture of 25* evaporated milk, 25%
Similac and 50* water. Lighting was provided by a 15 W
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bulb located on the back wall of each chamber. The room
in which the experiment took place was unlit. Standard
electromechanical programming equipment and cumulative
counters were used to control and record behavior.
Procedure
Phase I - Preliminary Trainin g
Animals were randomly assigned to one of three
operant chambers. Lever pressing for liquid food
reinforcement was shaped according to the method of
successive approximations. Once bar pressing was well
established on one of the levers, the food delivery
mechanism was inactivated for that lever and activated
for responses on the opposite lever. Practice trials
alternated between levers in this manner for the duration
of each 10 minute training period. In this way animals
were trained to alternate between response levers with
reinforcement initially being delivered on a continuous
reinforcement schedule. Gradually, the reinforcement
contingency was changed to a fixed ratio 10 (FR 10)
schedule of reinforcement with every 10th press on the
appropriate lever resulting in the presentation of 0.1 cc
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liquid reinforcement for a period of 3 s. This initial
training procedure was carried out on a daily basis
Monday through Friday for approximately 10 minutes/day at
roughly the same time of day between the hours of 11:00
a.m. and 2:00 p.m..
Phase XI - Drug Discrimination Training
After animals were consistently alternating between
levers and pressing on a FR 10 schedule of reinforcement,
drug discrimination training began. Animals were trained
to discriminate either m e thy 1 ph eni da te (Ritalin) or
imipramine (Tofranil) from vehicle (physiological
saline). ( M e t hy 1 ph e ni da t e hydrochloride and imipramine
hydrochloride were graciously supplied by the CIBA
Pharmaceutical Company, Summit, New Jersey.) Fifteen
animals were randomly assigned to the m e t hy 1 phe ni da t
e
group and fifteen to the imipramine group. On days when
an animal received drug, only responses on the drug lever
were reinforced; on saline days, only responses on the
saline lever were reinforced. For half the animals in
each group, the right lever was assigned as the drug
lever and the left as the saline lever. The lever
assignment was reversed for the remaining animals.
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For the methyl phenidate group, an initial starting
dose of 2.5 mg/kg was selected; for the imipramine group,
the starting dose was 10 mg/kg. The starting dose for
methylphenidate was based on a study by Huang and Ho
(1974) who found that the interoceptive cues used by rats
previously trained to discriminate 0.8 mg/kg d-
amphetamine from saline were g e n e r a 1 i z a b 1 e (90$
amphetamine lever choices) to methylphenidate when 2.5
mg/kg was injected. Drug was administered
intraperi toneal ly (i.p.) 30 minutes prior to training.
The rationale for this injection-training interval was
based on previous research (Silverman and Ho, 1977)
indicating that for methylphenidate at least,
discrimination begins to diminish one hour post injection
Drug discrimination sessions, 10 minutes in
duration, were carried out at approximately the same time
of day, once a day, for a minimum of five consecutive
days per week. Drug and saline days were varied so that
no animal was likely to select the correct lever because
of sequence repetition. Discrimination training
continued until an animal reached a final criterion of no
more than three incorrect lever presses prior to the
delivery of the first reinforcement on each daily 10
minute trial for nine out of ten consecutive sessions.
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Data were recorded in terms of percent drug lever
selection (% DLS). On drug days, the specific criterion
was 10/13 or 77$ DLS; on saline days it was 3/13 or 23%
DLS. Thus, low scores indicated a preference for the
saline lever; high scores, a preference for the drug
lever. The probability of reaching these criteria by
chance was less than .05. If an animal was unable to
discriminate drug from saline at the initial starting
dose, this dose was increased in increments of .5 mg/kg
for methylphenidate and 5 mg/kg for imipramine until the
final criterion was met.
Phase III - Subthreshold Dose Determination
Once an animal had reliably learned to discriminate
drug from saline as demonstrated by reaching criterion,
testing was conducted to determine its subthreshold of
discrimination. For example, if a particular animal had
learned to discriminate methylphenidate from saline at 3
mg/kg, this dose was reduced in increments of .5 mg/kg to
that dose which produced a % DLS score w hi cha p pr oa ch e
d
chance levels (~50*). Similarly, imipramine doses were
reduced by 5 mg/kg until responding approached chance
levels. On test days the animal was placed in the
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operant chamber and allowed to bar press until 10
responses had been made on one of the levers. If an
animal met the drug lever criterion on a particular test,
it was allowed to continue bar pressing for the duration
of the 10 min trial. If not, it was immediately removed
from the chamber and returned to its home cage.
Phase 11 - ImUifl Acid Drug Potentiation Teatlna
After an animal's subthreshold dose had been
determined, it was given its subthreshold dose along with
either tyrosine or tryptophan on the test day and allowed
to bar press until 10 responses were made on one of the
levers. Again, if an animal correctly discriminated that
it had drug as demonstrated by meeting criterion, it was
allowed to continue bar pressing for the remainder of the
10 minute trial; if not, it was returned to its home
cage. Me thy 1 ph eni da te animals were injected i.p. with
150 mg/kg dl-tyrosine suspended in saline and sonified to
further refine the suspension and facilitate injection.
Imipramine animals were given either 250 mg/kg l-
tryptophan or 150 mg/kg dl-tyrosine. Tryptophan was
suspended in propylene glycol and sonified.
Subthreshold dose and amino acid drug potentiation
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test sessions were usually carried out on Fridays
allowing for drug discrimination practice trials
to continue prior to testing. This insured that the
discrimination was still in place before the test day.
Animals whose drug lever selection was enhanced by
supplementing their subthreshold dose with amino acid
were subsequently tested with gradually reduced drug
doses, i.e., below subthreshold values, while the amino
acid dose was kept constant until % DLS scores again fell
to chance levels (~50#). On subsequent test days, these
animals were given the drug dose that produced chance
responding plus a higher dose of amino acid to see if
drug lever selection could once again be potentiated.
Tyrosine doses were increased stepwise by 25 mg/kg to a
maximum of 250 mg/kg; tryptophan, by 50 mg/kg to a
maximum of 300 mg/kg. Interspersed among the drug plus
amino acid trials were trials of the various amino acid
doses alone. On amino acid alone test days, animals were
always removed from the chamber after 10 responses had
been made on one of the levers.
CHAPTER III
RESULTS
In order for animal s to be considered as having
reliably discriminated drug from saline, they had to meet
a criterion of no more than three errors prior to the
delivery of the first reinforcer on each daily ten minute
trial for nine out of ten consecutive days. Mean + SEM %
DLS data for those ten criterion days for methylphenidate
and imipramine animal s are presented in Fig. 1.
Only data from animals that completed the first
three phases of the study are represented. Of the
original 15 methyl pheni date animals, 1 died five months
into the study of unknown causes. The remaining 1 k met
criterion and went on to complete the first three phases.
Of the original 15 imipramine animals, only 6 completed
the first three phases and all 6 met criterion. The
remaining 9 animals died at various times apparently from
drug related causes during the approximately sixteen
months it took to complete the study.
With respect to side effects, imipramine has been
known to decrease intestinal motility and increase urine
retention, side effects thought to be due to its
anticholinergic properties (Bassuk and Schoonover, 1977).
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Fig. 1. Mean ± SEM % drug lever selection at the
time of the first reinforcement for the 10 drug
discrimination criterion days. Saline vs. drug. High
scores indicate a preference for the drug lever; low
scores, a preference for the saline lever.
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For a few days prior to death, imipramine animals showed
the following symptoms: darkened and sometimes pus-laden
urine, dried blood around the nostrils, and hardened and
bloated abdomens. An autopsy on one of the animals
revealed a bloated and apparently obstructed intestinal
tract filled with semidigested food. Occasionally, death
could be postponed by eliminating drug trials for a
period of several days to a week. Most often, however,
once these symptoms appeared death soon followed. Those
animals that died demonstrated varying thresholds for the
development of these symptoms. Several animals developed
symptoms within two months. A few tolerated drug for as
long as eight months. All imipramine animals had
developed some symptoms by the time their participation
in the study ended. The limited ability of rats to
tolerate chronic administration of imipramine has been
noted elsewhere (Schecter, 1983).
The mean di s c r i m i na bl e dose for the ten day
criterion period was 3-32 mg/kg for m e t hy 1 ph e ni da t
e
animals and 19.17 mg/kg for imipramine animals.
Methyl phenidate animals took an average of 66 ± 10 days
to meet criterion; imipramine animals an average of 75 ±
18 days.
Once an animal reached criterion, its subthreshold
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dose was determined. Mean ± SEM % DLS data for the day
subthreshold doses were established for m ethyl phenidate
and imipramine animals are presented in Fig. 2. Fig. 2
clearly illustrates that drug lever selection for both
groups was well below chance (50$) and indicates a
significant preference for the saline lever. The mean
subthreshold dose for m e t hy 1 phe ni da t e and imipramine
animals was 1.5 mg/kg and 11.67 mg/kg, respectively.
Mean + SEM % DLS data for the ten consecutive days
prior to the establishment of subthreshold doses are
presented in Fig. 3, and demonstrate that animals were
reliably discriminating drug from saline prior to the
test day on which their subthreshold dose was
established.
Following this phase of the study, amino acid
potentiation testing began. Initially, each animal was
given its previously established subthreshold dose plus
amino acid. Me t hy 1 ph e ni da t e animals received i.p.
injections of drug followed by 150 mg/kg tyrosine;
imipramine animals, drug plus 250 mg/kg tryptophan or 150
mg/kg tyrosine, i.p.. Mean + SEM % DLS data for this
initial phase of amino acid drug potentiation testing for
both groups are presented in Fig. 4. Fig. 4 shows that
supplementation by amino acid of a subthreshold dose of
40
Fig. 2. Mean ± SEM % drug lever selection during the
test that established the subthreshold dose for
methylphenidate and imipramine. Low scores indicate a
preference for the saline lever.
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Fig. 3. Mean + SEM % drug lever selection during the
10 consecutive days just prior to the test day on which
the subthreshold dose was established.
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Fig. 4. Mean ± SEM % drug lever selection when
subthreshold drug doses were supplemented with amino
acids, tyrosine or tryptophan vs. subthreshold dose
alone. (Met hylpheni date was supplemented with tyrosine;
imipr amine with tyrosine or tryptophan.)
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drug enhanced drug lever selection in both
methylphenidate and imipramine groups as compared to a
subthreshold dose alone. in terms of the possible
differential effects of tyrosine vs. tryptophan on
imipramine potentiation, tyrosine potentiated a
subthreshold dose of drug in 2 of 3 imipramine animals;
tryptophan did so in 3 of 3 imipramine animals.
In order to determine whether amino acid by itself
would produce drug lever selection, all animals were
given the same kind and dose of amino acid they had
received on the amino acid drug potentiation test day.
Group means in terms of % DLS are presented in Fig. 5.
As can be seen, low DLS scores indicate that amino acid
alone produced relatively high levels of responding on
the saline lever for both methylphenidate and imipramine
groups. In terms of the possible differential effects of
tyrosine alone vs. tryptophan alone in eliciting a drug
response in imipramine animals (n=6), tyrosine alone
failed to elicit a drug response in 3 of 3 imipramine
animals (mean % DLS = 0.00); tryptophan alone elicited a
drug response in 1 of 3 imipramine animals (mean % DLS =
33.3).
Subthreshold dose, subthreshold dose plus amino
acid, and amino acid alone data (% DLS) were submitted to
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Fig. 5. Mean + SEM % drug lever selection after
amino acid alone administration. Methylphenidate vs.
imi pr ami ne
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a two-way mixed design analysis of variance. Raw data
were first transformed in accordance with the Arcsin
transformation procedure (Snedecor and Cochran, 1 967).
The main effect for groups ( methy lphenidate vs.
imipramine) was not found to be significant (P>0.05).
The main effect for trials (subthreshold dose vs.
subthreshold dose plus amino acid vs. amino acid alone)
was found to be significant (F 2>36=l4 . 78f P<0 .001). The
interaction of trials by groups was not significant
(P>0.05)
.
Post hoc tests involving orthogonal comparisons
between trial means indicated that trial two
(subthreshold dose plus amino acid) was significantly
different ( F 1
,
3 6
= 2
9
*
5
6
'
p<0 - 001 ) from the average of
trials one (subthreshold dose) and three (amino acid
alone), which did not differ significantly from each
other (P>0.05). Mean + SEM % DLS ( untr ansf or m ed data)
for trials one through three is presented in Figs. 6
(combined group data) and 7 ( m e t h y 1 p h e ni d a t e vs.
imi pr ami ne )
.
Upon completion of the initial amino acid alone
trials, an attempt was made to investigate whether even
lower subthreshold doses of drug would enhance drug lever
selection when supplemented by amino acid. Accordingly,
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Fig. 6, Comparison of mean + SEM % drug lever
selection across trials (combined group data).
Subthreshold dose vs. subthreshold dose plus amino acid
vs. amino acid alone.
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Fig. 7. Mean + SEM % drug lever selection across
trials (methylphenidate vs. imipramine).
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subthreshold doses were further decreased in stepwise
fashion by
.5 mg/kg for m e thy 1 ph eni da te and 5 mg/kg for
imipramine while the amino acid dose was kept constant.
When % DLS again fell to 50% or below, the same
subthreshold dose that produced this level of responding
was given while the amino acid dose was increased by 25
mg/kg for a maximum of 250 mg/kg tyrosine. Interspersed
among these subthreshold dose plus amino acid trials,
were trials of the various doses of amino acid alone.
Not all animals received this procedure due to time
constraints, the age of the animals by the time of
testing, and the high mortality of imipramine animals.
Data on several animals that completed most of this
process in a systematic fashion are presented in table 1.
An inspection of the data in table 1 reveals the
following: (1) There is a clear indication that even
lower subthreshold doses of drug in the same animal can
be potentiated by amino acid supplementation. This
effect was demonstrated in 7 of 11 animals. (2) When a
subthreshold dose of drug plus amino acid no longer
produced a clear cut preference for the drug lever in an
animal, drug lever selection could often be enhanced by
increasing the amino acid dose while keeping the drug
dose constant. This effect was demonstrated in 5 of 8
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Table I
% Drug Lever Selection (DLS) From Subsequent Testing inWhich Subthreshold Doses of Drug Were Decreased andVarying Doses of Amino Acid Were Administered Alone and
in Combination With Drug (doses are given in mg/kg).
S Subthreshold %DLS Subthreshold 1 DI ^P iJ i_i O yb U L> o
Do se Dose & Tyr
1 3 MPD 9 J « 15 0 1 00 i cn Q
2.5 & 150 7 1 n
2 & 150 71 175 0
1 .5 & 150 23 1 75 0
1 .
5
& 175 100 200 0
o n n nU
2 1.5 MPD nw 1 .5 & 1 50 1 n n i nn
1 & 150 1 n n i cn nu
. 5 & 150 0 175 1 00
.5 & 175 1 n n
j j li r u 3 & 1 50 P 3^ j 1 R 0 77
3 & 175 7 1 c< CD ->
3 & 200 1 n n
4 1 MPD 1*1 1 & 1 50 47 150 9
1 & 200 58 1 50 0
1 & 250 9 175 0
175 0
200 91
200 0
5 1.5 MPD 0 1 .5 & 150 0 150 0
1 .5 & 175 100 1 50 0
175 100
200 0
200 0
Note. S = subject , Tyr = tyrosine, MPD = methylpheni date,
IMIP = imipramine.
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Table I Continued
p DL O Su bthr eshol
d
5&DLS Tyr J DLSDose Dose & Tyr
6 1 MPD 23 1 & 150 1 00 150 1 7
.5 & 150 1 00
PR JL 1 cn )l 14 1
.25 & 175 9
.25 & 200 2Q
.25 & 250 Q
7 2 MPD 33 2 & 150 1 00 1 50 Q
1.5 & 150 91 175 1 00
1 *7 C
1 ( 5 23
200 0
9 1.5 MPD 0 1.5 & 150 1 00 1 50 9 1
1 & 1 50 o 1 50 0
1 & 175 23 175 0
1 & 200 n 1 7 R nu
1 & 250 0 200 0
1 & 250 38 200 0
11 P M Pfiii c Li r u 1 7 P & 1 R 0 10 0 1 R 0 o
1.5 & 150 100 175 83
1 & 1 50 100 175 0
.5 & 150 1 00 200 55
.25 & 150 100
17 1 c; TMTP 1 R & 15 0 1 00 1 50 0
10 & 150 1 00
5 & 150 23
20 10 IMIP 63 10 & 150 1 00 1 50 0
5 & 150 100
2.5 & 150 100
2 & 150 0
2 & 175 1 00
Note. S = subject , Tyr = tyrosine, MPD = me thylphenidate
IMIP = imipr amine .
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animals. (3) While amino acid alone sometimes produced
drug lever selection, this effect did not appear to be
dose related nor was it consistent within or between
animal s
.
Finally, in order to determine whether animals 1
subthreshold doses were subject to change over time due
to the development of tolerance or increased sensitivity,
subthreshold doses were re-evaluated for some animals.
In most instances, this testing took place several weeks
to a few months after the initial subthreshold dose had
been established. Of the 13 animals tested in this way,
the subthreshold dose had decreased in 8, remained the
same for 2
,
and increased in 3.
CHAPTER IV
DISCUSSION
The purpose of this study was to examine whether a
drug that enhances the action of a neurotransmitter can
be potentiated by an exogenous supply of a nutrient which
serves as a precursor for that neurotransmitter. In this
case, we examined whether the action of methyl pheni date
and imipramine could be enhanced by supplying exogenous
sources of tyrosine or tryptophan. The behavior of rats
bar pressing for food reward in a dr ug- co n t r ol 1 e d two-
lever choice situation was used to evaluate drug and
amino acid effects.
The results indicate that the interoceptive cues
used by animals to discriminate m e t hy 1 ph e ni da t e or
imipramine from vehicle were potentiated by i.p.
injections of tyrosine or tryptophan when subthreshold
doses of these drugs were administered. This
potentiation was able to control responding on the drug
lever. Moreover, it appears that drug effects cannot be
produced in this paradigm solely by administering the
appropriate amino acid precursor; some drug, albeit in
subthreshold amounts, has to be present. In trials in
which subthreshold doses were reduced until the
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combination of drug plus amino acid no longer produced a
drug induced response, simply increasing the dose of
amino acid in several animals reinstated the response.
In other trials in which larger doses of amino acid alone
were tested, a few drug responses occurred but this
effect was sporadic and did not appear to be dose
related. It may be that the amino acid alone doses were,
in general, too large. Badawy and Williams (1982) have
suggested that the ability of exogenous tyrosine to
enhance CA synthesis and release may be dose related with
smaller doses being more effective than larger ones. In
their study, tyrosine doses of up to 40 mg/kg were found
to produce significant increases in DOPA accumulation in
rat brain but only the 20 mg/kg dose increased brain DA,
DOPAC, and NE to a significant degree. Doses of 50 mg/kg
and over abolished this enhancement. Badawy and Williams
suggest that this may have been due to substrate
inhibition of tyrosine hydroxylase activity.
With respect to tyrosine, our finding that
subthreshold amounts of drug, e.g., methy lphenidate, must
be present for amino acid potentiation to occur was not
contrary to expectation as the enzyme which catalyzes the
key step in the conversion of tyrosine to
neurotransmitter is subject to end-product inhibition
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arising both from intracellular and extracellular events
(Wurtman et al., 1981), Increasing the level of
neurotransmitter by precursor loading ul timately serves
to inhibit synthesis and release. In this study we may
have effectively overcome this type of feedback
inhibition on tyrosine hydroxylase by supplying low doses
of drug which may have served to increase synaptic
activity. Under these conditions, increased levels of
precursor in brain may have led to more neurotransmitter
release and thus a potentiation of drug effects. This
finding is consistent with the results of other studies
(Melamed et al., 1980; Wurtman et al., 1981) suggesting
that tyrosine's ability to influence the synthesis and
release of CAs may depend upon neuronal activity -
increasing when populations of neurons are firing
frequently and decreasing when they are relatively
quiescent.
This does not preclude the possibility that tyrosine
administration alone may be useful in the treatment of
ADD or for that matter other disorders thought to be due
to decreased functioning within select populations of CA
neurons. For exam pie, tyrosine inj ection has been shown
to significantly lower blood pressure in spontaneously
hypertensive rats (Sved et al., 1979), and to increase
6 1
blood pressure in hypotensive rats (Conlay, Maher and
Wurtman, 1981). There is also some indication that
tyrosine may be useful in the treatment of unipolar
depression (Gibson and Gelenberg, 1983).
Perhaps those patients who will ultimately respond
to tyrosine therapy alone represent a subgroup of
patients who have abnormally low levels of plasma and/or
brain tyrosine to begin with due perhaps to dietary
influences or an as yet unidentified deficit in the
transport system which carries tyrosine across the blood
brain barrier.
In terms of tryptophan, our results are more
equivocal with respect to whether tryptophan can elicit a
drug effect in the absence of low doses of imipramine.
Tryptophan was difficult to get into an injectable
solution. Because of this as well as the high mortality
of imipramine animals due to the side effects of this
drug, imipramine animals did not have many tryptophan
alone trials. More data are needed in order to determine
more fully the efficacy of tryptophan alone in producing
a drug response.
Unlike tyrosine hydroxylase, tryptophan hydroxylase
is not reported to be significantly affected by end-
product inhibition (Jacoby et al., 1975) so that
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increased amounts of precursor should lead to increased
synthesis and release. There is some evidence to support
this (Fernstrom and Wurtman, 1971; McBride et al., 1976).
On the other hand, imipramine has been reported to be a
more potent NE than 5-HT reuptake inhibitor (Green and
Nutt, 1983). If the interoceptive cues produced by
imipramine were primarily related to its effects on NE
rather than 5-HT, this would be consistent with our
preliminary finding that tryptophan alone does not
consistently elicit a drug response. The fact that
tryptophan was able to potentiate subthreshold doses of
imipramine in 3 out of 3 animals tested in this way
suggests that drug effects involve a more complex
interaction between 5-HT and NE. This is supported
further by the finding that tyrosine and tryptophan were
both effective in producing a drug response in the
presence of subthreshold doses of imipramine.
It should be pointed out, however, that the tyrosine
dose (.83 mmol/kg) was considerably less than the
tryptophan dose (1.22 mmol/kg). There has been at least
one report in the literature on the differential effects
of tyrosine vs. tryptophan on the same physiological
phenomenon (Sved et al., 1 97 9 ). In their study, Sved et
al. found that tryptophan injection (225 mg/kg) lowered
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blood pressure in spontaneously hypertensive rats but
only by about half as much as an equivalent dose of
ty r o si ne .
Another possible explanation, as well as a more
parsimonious one for the failure of tryptophan to elicit
a drug response, is the following. Imipramine is known
to have effects on multiple neurotransmitter systems,
e.g., cholinergic and histaminergic as well as
monoami ner gic (Iversen and Mackay, 1979). Amino acids on
the other hand affect only the neurotransmitter systems
for which they serve as precursors although it is
possible that there may be indirect effects on other
neurotransmitter systems as well. If the interoceptive
cues used by our animals to discriminate imipramine were
related to its effects on multiple neurotransmitter
systems, then the failure of tryptophan alone to produce
a drug response can be easily under stood.
Finally, the failure of tryptophan to produce a drug
response does not preclude the possibility that
tryptophan therapy may be effective in the treatment of
disorders associated with decreased functioning in
populations of 5-HT neurons, especially if the putative
deficits are specifically confined to this system.
Tryptophan has been used alone and in combination with
6n
antidepressant drugs in clinical trials for the treatment
of depression although, as previously mentioned, the
results have been inconsistent (Chouinard et al., 1983;
Walinder, 1 9 8 3 )
.
One possibility that was not investigated was that
the potentiation of drug effects by amino acid was due to
a non-specific amino acid effect. In order to test this
hypothesis, another amino acid such as valine which uses
the same transport system into brain as tyrosine and
tryptophan but which does not serve as a precursor for
the CAs or 5-HT could have been given along with
subthreshold doses of drug to a control group of animals.
However, Morre et al. (1980) have shown that increases in
brain tyrosine produced by tyrosine injection (100 mg/kg)
can be blocked by the co- adm i ni s t r a t i o n of valine (500
mg/kg). In addition, it has been demonstrated (Wurtman
et al., 1974) that tyrosine (50 mg/kg) but not leucine
(100 mg/kg) or tryptophan (50 mg/kg) can produce
significant increases in DOPA accumulation in rat brain
following decarboxylase inhibition. These studies
suggest that in the case of tyrosine at least we are not
dealing with a non-specific amino acid effect.
It is also possible that in the intervening time
("1-2 weeks) between the establishment of the
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subthreshold dose for each animal and the amino acid plus
subthreshold dose trials, animals' thresholds changed and
they "got better" at discriminating drug. For some of
our animals, several weeks to a few months after the
first phases of testing were completed, we repeated the
procedure for determining the subthreshold dose to assess
the possibility that either tolerance or an increased
sensitivity to the drug had developed. Of the 13 animals
tested, the subthreshold dose had remained the same in 2,
increased in 3 and decreased in 8. Those animals whose
subthreshold dose had increased or remained the same
happened to have had fewer (Mean ± SEM = 14.8 + 3.1) drug
trials during the intervening period than those whose
subthreshold dose had decreased (Mean + SEM = 28.6 ±
2.7). Thus it appears that subthreshold doses may have
changed over the course of repeated trials perhaps
increasing in the short term and decreasing over the long
term. When we tested 4 of the animals whose
subthresholds had subsequently decreased with their new
subthreshold dose plus 150 mg/kg tyrosine, drug lever
selection was not enhanced; however, we reinstated the
enhancement effect in 3 of these 4 animals by increasing
the dose of amino acid while keeping the new subthreshold
dose constant. These findings support the supposition
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that we are dealing with a true potentiation effect and
not an artifact of increased sensitivity to drug.
An interesting phenomenon which was observed in the
majority of our animals and which may point to possible
side effects accompanying the administration of doses of
amino acids substantially above those normally present in
diet was the following: Almost immediately after being
injected with tyrosine or tryptophan, animals appeared to
become sedated, often lying down on their sides in their
home cages. If approached by an experimenter they would
often struggle to get up and appeared unsteady. When
handled they were somewhat flaccid to the touch and
seemed to have experienced a loss of muscle tone. If
placed on a flat surface at this time and allowed freedom
of movement, they often wobbled about and had difficulty
staying on their feet. These effects were temporary
however, and animals appeared to be back to normal by the
time they were to be tested, 30-45 minutes later.
Animals seemed to vary in the degree to which they
manifested these symptom s. Over the course of repeated
amino acid injections, a few animals appeared to develop
a tolerance to this effect. Of interest is the
observation that these behavioral symptoms occurred
whether amino acid was injected alone or in combination
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with drug.
There is evidence that excessively large doses of
tryptophan are toxic (Gullino, Winitz, Birnbaun,
Cornfeld, Otey and Greenstein, 1956). Symptoms of
toxicity which appear as early as 10 minutes post
injection include dyspnea, hypothermia, and extreme
prostration often connected with uncoordinated movement.
The LD^q f or a d u it male rats is 8 mmol/kg body weight for
the 1-isomer. This dose represents more than 1.5 g/kg of
1-tryptophan or 80-120 g for an adult human (Sourkes,
1983). When an LD99.9 < 12 mmol/kg) of 1-tryptophan was
given to rats, a severe but transient hyperglycemia
resulted and animals ultimately died in a hypoglycemic
state (Winitz, Gullino, Greenstein, and Birnbaum, 1956).
A dose of 750 mg/kg of 1-tryptophan administered
i.p. to both fed and food deprived (36 h) rats produced
an initial hyperglycemia after 1.5 h followed by a return
to normal blood glucose concentrations after 3 h,
followed by a period of severe hypoglycemia; blood
glucose levels then slowly returned to initial values
(Smith and Pogson, 1976). The hypoglycemic effect of
tryptophan was potentiated in animals pretreated with
pargyline, a monoamine oxidase inhibitor and blocked in
animals pretreated with the 5-HT antagonist,
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methy sergide, suggesting the involvement of 5-HT. This
effect was found to be dependent on the presence of
functional pancreatic beta cells suggesting that insulin
is also involved. Perhaps what we observed in our
animals given 250 mg/kg 1-tryptophan was a mild and
transient hyperglycemic state. This possibility is
currently under investigation in our lab.
Finally, the question arises as to whether the
interoceptive cues used by animals in this drug
discrimination paradigm were central or peripheral.
Indirect evidence that the methyl phenidate cue at least
may be central comes from two experiments by Richards,
Harris and Ho (1973) on the discriminative stimulus
properties of d- am ph e t am i ne , a drug which is closely
related, pharmacologically, to methyl phenidate. In the
first experiment, two groups of rats implanted with
intraventricular cannulae were trained to discriminate d-
amphetamine (0.5 and 1.5 mg/kg, i.p.) from saline in a
two-lever choice situation. Both groups responded on the
saline lever to i.p. injections of 2 mg/kg p-
hydroxyamphetamine (p-OHA), a drug which has peripheral
effects similar to amphetamine but possess little central
activity due to its limited ability to cross the blood-
brain barrier (Silverman and Ho, 1977). Central
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administration of 50 ug or more of d- am phe tami ne in the
0.5 mg/kg group and 75-100 ug or more in the 1.5 mg/kg
group produced responding on the drug lever. In the
second experiment, two groups of rats were trained to
discriminate intraventricular injections of amphetamine
(150 ug) from saline and then tested to see if drug lever
responding would generalize to i.p. injections of 0.5 and
1.5 mg/kg amphetamine, 1 mg/kg saline, and 2.0 mg/kg (p-
OHA). Again, animals responded on the drug lever to d-
amphetamine but not to p-OHA. The results of both
experiments demonstrate that central rather than
peripheral cues are involved in the discriminative
stimulus properties of d-amphetamine.
In summary, the following conclusions seem to be
warranted on the basis of our findings: First,
psychoactive drugs such as m ethyl phenidate and imipramine
used in the treatment of ADD may be potentiated by
exogenous supplies of amino acids which serve as
precursors to the neurotransmitters on which these drugs
ultimately act. As such, it may be possible to attenuate
or eliminate some of the side effects produced by these
drugs while still maintaining their theraputic efficacy.
This possibility may be of considerable interest to
parents and professionals who are resistant to medicating
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young children and adolescents often because of these
side effects. To date, as far as can be determined, no
studies have attempted to use tyrosine or tryptophan in
combination with methylphenidate or imipramine in the
treatment of ADD, al though our results suggest that such
studies may be warranted. Second, the experimental
paradigm used in this study seems to offer a viable
animal model within which to study this drug potentiation
phenomenon as a whole, offering as it does a better
degree of control than is typically possible with
clinical populations. Third, follow-up studies are
needed to determine if the potentiation of the behavioral
effects of these drugs by amino acid can be supported by
neurochemical studies demonstrating an increase in
neurotransmitter turnover in the presence of a dose of
drug plus amino acid when compared to that same dose of
drug alone. This type of investigation is now in
progress in our lab.
Finally, Wender (1975) has hypothesized that ADD may
involve a functional underactivity in one or more of the
monoamine neurotransmitter systems due to decreased
synthesis, release or receptor sensitivity. It is also
possible that this presumed functional underactivity may
be a result of a lower than normal number of
neurons in
71
one of these systems leading to secondary deficits in
neurotransmitter and biosynthetic enzyme activity within
brain. There is evidence, for example, that genetically
related natural variations in the number of DA neurons
within brain are responsible for observed neurochemical
(tyrosine hydroxylase activity)
,
morphological (receptor
density; size of target organ), pharmacologic
(sensitivity to the effects of d-amphetamine) and
behavioral (spontaneous motor activity and exploration)
differences found in two different strains of mice (Reis,
Fink, Baker, 1983). Perhaps the ADDchild or adult
represents an extreme of a temperament continuum, the
underlying physiological basis for which may involve
genetically related natural variations in numbers of CNS
neurons of a particular neurochemical type. In any case,
supplying more precursor while simultaneously priming the
system with drug could theoretically com pen sate for this
hypothetical deficit.
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